» Articles » PMID: 19479206

Expanding and Converting Regulatory T Cells: a Horizon for Immunotherapy

Overview
Publisher Sciendo
Date 2009 May 30
PMID 19479206
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The human immune system is a myriad of diverse cellular populations, each contributing to maintaining an effective and optimal immune response against infectious agents. It is important to maintain a "self-check" in the immune system so that responses do not go haywire, leading to the development of autoimmune diseases. Regulatory/suppressor T (Treg) cells are a specialized subpopulation of T cells that suppress the activation, expansion, and function of other T cells, thereby maintaining homeostasis through a fine balance between reactivity to foreign and self antigens. Tregs are characterized by surface expression of interleukin (IL)-2 receptor alpha chain (CD25) and intracellular expression of forkhead box protein P3 (FoxP3). There are at least two important functional populations of Treg cells, namely natural Treg (nTreg), which are continuously derived from the thymus, and induced Treg (iTreg), which are converted from naive T cells. The development and function of both nTreg and iTreg cells are regulated by several factors, such as antigen T-cell receptor, co-stimulatory receptors (i.e., cytotoxic T lymphocyte-associated antigen, or CTLA-4), and cytokines (IL-2, IL-10, and tumor growth factor-beta, or TGF-beta). In addition, the TGF-beta inhibitor ALK5, retinoid acid, and rapamycin influence the expansion of nTreg cells and the conversion of iTreg cells in vitro and in vivo. The heightening of Treg expansion may be harnessed to therapeutic methods for the treatment of autoimmune diseases and the induction of transplantation tolerance.

Citing Articles

Bibliometric analysis of global research trends on regulatory T cells in neurological diseases.

Gao Q, Li X, Li Y, Long J, Pan M, Wang J Front Neurol. 2023; 14:1284501.

PMID: 37900596 PMC: 10603183. DOI: 10.3389/fneur.2023.1284501.


Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P Immunology. 2020; 162(2):160-178.

PMID: 32939758 PMC: 7808166. DOI: 10.1111/imm.13264.


A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.

Chen X, Ai X, Wu C, Wang H, Zeng G, Yang P Cell Death Dis. 2018; 9(10):989.

PMID: 30250191 PMC: 6155133. DOI: 10.1038/s41419-018-1047-2.


Microbiota, Epithelium, Inflammation, and TGF-β Signaling: An Intricate Interaction in Oncogenesis.

Pang X, Tang Y, Ren X, Chen Q, Tang Y, Liang X Front Microbiol. 2018; 9:1353.

PMID: 29997586 PMC: 6029488. DOI: 10.3389/fmicb.2018.01353.


Anti-TCRβ mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice.

Xie A, Li R, Jiang T, Yan H, Zhang H, Yang Y Endocrinology. 2017; 158(10):3140-3151.

PMID: 28977608 PMC: 5659705. DOI: 10.1210/en.2016-1947.